medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2010, Number 593

<< Back Next >>

Rev Med Cos Cen 2010; 67 (593)

Crisis migrañosa: Guía diagnóstica y abordaje terapéutico

Pérez MA, Mora LE

Language: Spanish
References: 35
Page: 271-276
PDF size: 343.21 Kb.


ABSTRACT

Migraine headache is the cause of a very frequent ask of adviceworldwide. It represents a social, economic and important problem due to its recurrent, changeable and disabling effects. The complete knowledge of the international diagnostic criterion for the familial subtypes of migraine headache is yielding information which represents the unavoidable requirement to decrease the number of wrong diagnosis. There is a tendency of an excessive handling o, diagnosis for migraine related to the disregard about specific mechanisms that underlie these events and what they do, or don’t do, to cause the pain. As a consequence, there is not any reason to start an effective therapeutic scheme by prescribing medicines to patients who do not really need them. Several drugs could prevent or interrupt a migraine attack but they could not be suitable for any related pain. Understanding the cascade of biological events that happen in the brain to cause migraine will give opportunities to all doctors and patients to choose the appropriate medication according to severity of pain, presence of associated symptoms and the frequency of the crisis.


REFERENCES

  1. AVNON Y, Y OTROS. Different patterns of parasympathetic activation in uni and bilateral migraineurs. Brain. 2003. Vol 126: 1660-1670.

  2. BARTSCH T, GOADSBY P. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003. vol 126. pags 1801-1813.

  3. BOHOTIN V, Y OTROS. Effects of repetive transcranial magnetic stimulation on visual evoked potentials in migraine. Brain 2002. Vol 125: 912-922.

  4. CADY R, DODICK D. Diagnosis and Treatment of Migraine. Mayo Clin Proc.2002. Vol 77. pags 255-261.

  5. CANO-GARCIA F, RODRIGUEZ-FRANCO L. Validez de los criterios de la Sociedad Intemacional de Cefaleas en el diagn6stico de migrafia y cefalea tensional. Rev Neurologta 2003. vol 36. pags 710-714.

  6. COLINA-GARCIA R, CARRASQUERO-ARJAS S. Valor diagn6stico de los criterios de la IHS en el diagnóstico diferencial de las cefaleas primarias. Rev neurologia 2003. vol 36. pags 903 - 906.

  7. COLOGNO D, TORELLI P, MANZONI GC. A prospective study of the headache phase in 32 migraine with aura patients. Cenhalalria. 2002. Vol 22. nag 411-415.

  8. CROFFORD L. Rational use of analgesic and antiinflamatory drugs. New England Journal of Medicine. 2001. Vol 345, No25.Pagl844.1846.

  9. DIAMOND M. The role of concomitant headache types and non-headache comorbidities in the under diagnosis of migraine. Neurology. 2002. Vol 58, supl 6: S3-S9.

  10. Dffi M, Y OTROS. Efficacy of oral ketoprofen in acute migraine. Neurology 2002. Vol 58: 1660-1665.

  11. ELRINGTON G. Migraine: Diagnosis and Management. Journal Neurology Neurosurgery Psychiatry. 2002. Vol 72 suppi II.

  12. ETMINAN M Y OTROS. Efficacy of Angiotensin II receptor agonista in preventing headache. American Journal of Medicine. 2002. Vol 112, pag 642-646.

  13. FERRARI, GOADSBY PJ, ROON KI, LIPTON RB. Triptans (serotonin, 5-HT 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002. Vol 22, pag 633-658.

  14. FREITAG F, Y OTROS. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002. Vol 58: 1652-1659.

  15. GIFFIN N, Y OTROS. Premonitory symptoms in migraine. Neurology 2003. Vol 60: 935-940.

  16. GOADSBY P, Y OTROS. Adenosine A 1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002. Vol 125: 1392-1401.

  17. GOADSBY P, LIPTON R, FERRARI M. Migraine - Current understanding and treatment. New England Journal of Medicine. 2002. Vol 346, No 4.

  18. HENRY P, Y OTROS. Prevalence and clinical characteristics of migraine in France. Neurology 2002. Vol 59:232-237.

  19. JENSEN K, Y OTROS. Classic migraine, a prospective recording of symptoms. Acta Neurol Scand 1986; 73: 359-362.

  20. KANIECKI R. Migraine and tension-type headache. Neurology. 2002, vol 58, supl 6. pags S 15-S20.

  21. KAUBE H, Y OTROS. Acute migraine headache. Possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002. vol 58: 1234-1238.

  22. KAUBE H,Y OTROS. Acute migraine headache. Neurology 2002. vol 58. pag 1234 - 1238.

  23. KEAM S.J, GOA K.L, FIGGIT D.P. Almotriptan. A review of its use in migraine. Drugs. 2002; vol 62, No 2. Pag 387-414.

  24. KRYMCHANTOWSKI V. Overuse of symptomatic medications among chronic migraine patients. Arquivos Neuropsiquiatria. 2003. Vol 61:43-47.

  25. LEE H, Y OTROS. Hearing symptoms in migranous infarction. Archives Neurology. 2003. Vol 60. pags 113-116.

  26. LIPTON R, Y OTROS. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003. Vol 60:441-448.

  27. LIPTON R Y OTROS. Self-awareness of migraine. Neurology. 2002. vol 58, supl 6. pag S21-S26.

  28. MONDA VD, Y OTROS. Efficacy of a fixed combination of indometacin, prochlorperazine and caffeine versus sumatriptan in acute treatment of multiple migraine attacks. Headache. 2003; vol 43, No 8. Pag 835-844.

  29. RAINS J, PENZIEN D, LIPCHBC G, RAMADAN N. Diagnosis of migraine: empirical analysis of a large clinical sample of atypical migraine (HIS 1.7) patients and proposed revision of the MS criteria. C’eohalalgia. 2001. Vol 21, pag 584-595.

  30. SANDRTNI G, FARKKILA M, BURGESS G, FORSTER E, HAUGHIE S. Eletriptan vs Sumatriptan. Neurology. 2002: vol59.Pagl210.1217.

  31. SHECTER A, STEWART W, SILBERSTEIN S, LIPTON R. Migraine and autonomic nervous system function. Neurology 2002. Vol 58:422-427,

  32. SIBERSTEIN S, LIPTON R, GOADSBY P. Headache in Clinical Practice. ISIS Medical Media. 1998.

  33. SNOW V, WEISS K, WALL E, MOTTUR-PILSON CH. Pharmaeologic management of acute attacks of migraine and prevention of migraine headache. Annals of Internal Medicine. 2002. Vol 137.

  34. TEPPER S.J, RAPOPORT A.M, SHEFTELL F.D. Mechanisms of Action of the 5-HT 1B/1D receptor agonists. Archives of neurology. 2002. Vol 59 Pag 1084-1088.

  35. TRONVIK E, STOVNER L, HELDE G, SAND T, BOVIM G. Prophylactic treatment of migraine with an Angiotensin II receptor blocker. JAMA. 2003. Vol 289, No 1.




2020     |     www.medigraphic.com